Optically active bridged piperidine derivative
AssigneeSumitomo Pharma Co., Ltd.
InventorsSeiji Kamioka, Naoaki Shimada, Hitoshi Ban, Kazuto Yamazaki, Akihiko Arakawa, Wataru Hirose
Life of this patent
Estimating the term…
Abstract
The present invention relates to the compound of formula (1a) wherein a-d and p are 1 or 2, R1-R4 are hydrogen atom or the like, and R18 is —CF3 or the like, or a pharmaceutically acceptable salt thereof, which has an anticancer effect by inhibiting the binding between a MLL fusion protein that is fused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.
Claims10
A compound selected from the group consisting of
- [(1S,3S,4R)-5-(2H2)methylidene-2-azabicyclo[2.2.2]octan-3-yl]{2-[2-(2,2,2-trifluoroethyl)-5-(trifluoromethyl)thieno[2,3-b]pyridin-4-yl]-2,7-diazaspiro[3.5]nonan-7-yl}methanone,
- 4-{7-[(1S,3S,4R)-5-(2H2)methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}-2-(2,2,2-trifluoroethyl)thieno[2,3-b]pyridine-5-carbonitrile,
- 4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.1]heptane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}-2-(2,2,2-trifluoroethyl)thieno[2,3-b]pyridine-5-carbonitrile,
- [(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octan-3-yl]{2-[2-(2,2,2-trifluoroethyl)-5-(trifluoromethyl)thieno[2,3-b]pyridin-4-yl]-2,7-diazaspiro[3.5]nonan-7-yl}methanone, and
- 4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}-2-(2,2,2-trifluoroethyl)thieno[2,3-b]pyridine-5-carbonitrile or pharmaceutically acceptable salt thereof.
A compound selected from the group consisting of [(1S,3S,4R)-5-(2H2)methylidene-2-azabicyclo[2.2.2]octan-3-yl]{2-[2-(2,2,2-trifluoroethyl)-5-(trifluoromethyl)thieno[2,3-b]pyridin-4-yl]-2,7-diazaspiro[3.5]nonan-7-yl}methanone, or a pharmaceutically acceptable salt thereof and 4-{7-[(1S,3S,4R)-5-(2H2)methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}-2-(2,2,2-trifluoroethyl)thieno[2,3-b]pyridine-5-carbonitrile, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.